A verifiable KPV COA confirms the exact chemical identity, molecular mass, and chromatographic purity of the Lys-Pro-Val tripeptide sequence. For laboratories evaluating a KPV 10mg/vial format, independent analytical verification via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS) ensures sequence fidelity, minimal trifluoroacetate (TFA) salts, and batch-to-batch consistency in cell culture and preclinical assays.
A verifiable KPV COA confirms the exact chemical identity, molecular mass, and chromatographic purity of the Lys-Pro-Val tripeptide sequence. For laboratories evaluating a KPV 10mg/vial format, independent analytical verification via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS) ensures sequence fidelity, minimal trifluoroacetate (TFA) salts, and batch-to-batch consistency in cell culture and preclinical assays.
KPV is a C-terminal tripeptide fragment—specifically Lysine-Proline-Valine—derived from the naturally occurring neuropeptide alpha-Melanocyte-Stimulating Hormone (alpha-MSH). In preclinical biochemical literature, this sequence is isolated to examine its targeted anti-inflammatory properties without eliciting the melanogenic receptor activation associated with full-length melanocortin peptides. Researchers utilizing KPV 10mg vials evaluate its capacity to downregulate nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) transcription without activating pigment-inducing pathways.
Due to its short three-amino-acid backbone (molecular weight approximately 341.45 g/mol), KPV presents distinct handling and stability characteristics compared to larger helical proteins. Researchers sourcing from our all peptides catalog require detailed structural verification to confirm that the C-terminal carboxylic acid and N-terminal amine groups remain uncompromised by side-chain degradation during solid-phase peptide synthesis (SPPS).
A rigorous **KPV COA** serves as the primary document validating lot-specific quality before experimental deployment. When reviewing analytical documentation, research institutions should first scrutinize the Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) chromatogram. The principal peak corresponding to the Lys-Pro-Val sequence must demonstrate an area-under-the-curve (AUC) purity metric exceeding 98.0%, with total secondary synthesis impurities restricted to under 1.0%.
Complementing HPLC, Electrospray Ionization Mass Spectrometry (ESI-MS) confirms molecular weight. On an official test document, the observed [M+H]+ mass-to-charge ratio (m/z) must match the theoretical molecular weight of 342.45 m/z within a strict tolerance window (±0.5 Da). To review verified test reports across our non-clinical compound catalog, explore our centralized research library for full lot analytical transparency.
Selecting a standardized **KPV 10mg/vial** specification provides laboratory technicians with a repeatable target mass for precise micro-molar solution preparation. To guarantee analytical precision across longitudinal assays, research compounds must meet strict manufacturing and laboratory testing parameters before release:
• **Purity Threshold:** ≥98% purity verified via RP-HPLC with documented UV absorption spectra. • **Identity Verification:** ESI-MS confirmation of the 341.45 g/mol primary structure. • **Endotoxin Control:** Bacterial endotoxin level verified at <0.01 EU/mg via Chromogenic LAL Assay. • **Residual Solvent Testing:** Gas chromatography (GC-MS) validation confirming sub-ppm levels of synthesis reagents. • **Lyophilization Integrity:** Uniform, moisture-controlled cake matrix packaged under dry argon in USP Type I borosilicate glass.
In vitro and animal model investigations primarily assess KPV within models of intestinal epithelial breach and localized inflammatory cascades. Preclinical studies indicate that KPV enters intestinal epithelial cells via the peptide transporter PepT1 (SLC15A1). Once internalized, the tripeptide interacts with intracellular signaling pathways to attenuate pro-inflammatory cytokine expression, including interleukin-6 (IL-6), interleukin-1 beta (IL-1β), and tumor necrosis factor-alpha (TNF-α).
In murine models of dextran sulfate sodium (DSS)-induced colitis, researchers observe that KPV administration preserves tight junction protein expression—specifically Zonula Occludens-1 (ZO-1) and Occludin. These findings position KPV as a key subject in molecular studies published within our anti-inflammatory peptides research hub, highlighting its utility in probing mucosal healing dynamics without broad systemic immunosuppression.
When designing comparative research protocols for tissue boundary dynamics and cytoprotection, investigators frequently benchmark KPV against other established barrier-modulating compounds. While KPV acts primarily via intracellular PepT1 transport and NF-κB inhibition, BPC-157 10mg operates predominantly through VEGF pathway modulation, nitric oxide (NO) synthesis, and focal adhesion kinase activation. In contrast, compounds such as TB-500 10mg influence cellular migration via actin monomer sequestration (Thymosin Beta-4 domain dynamics).
Selecting the optimal peptide depends on the specific cellular target. While BPC-157 offers broad tissue remodeling capabilities and TB-500 drives cell motility, KPV provides a targeted probe for PepT1-mediated transport and direct nuclear factor attenuation. Laboratories conducting parallel compound comparisons can set up institutional accounts through our wholesale peptide portal to streamline multi-target experimental supplies.
To maintain peptide integrity when opening a lyophilized **KPV 10mg vial**, laboratory personnel should adhere to strict aseptic techniques under a laminar flow hood. Allow the sealed borosilicate vial to equilibrate to room temperature (20°C to 25°C) prior to reconstitution to prevent moisture condensation within the matrix upon vacuum break.
Reconstitute the sample using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile phosphate-buffered saline (PBS, pH 7.4), depending on down-stream assay sensitivity. Gently introduce the diluent along the internal glass wall rather than directly onto the lyophilized cake. Swirl gently until complete dissolution occurs; never vortex high-purity peptide solutions, as mechanical shear forces can disrupt peptide-solvent equilibria. For further protocol guidance, visit our peptide handling guidelines.
Lyophilized KPV tripeptide exhibits excellent long-term chemical stability when stored in an ultra-low temperature freezer (-20°C to -80°C) protected from direct light exposure. Under these conditions, the un-reconstituted powder maintains identity and purity specifications for up to 24 months as documented on the primary lot analysis.
Once solubilized in sterile aqueous media, stock solutions should be divided into single-use experimental aliquots using low-binding polypropylene microcentrifuge tubes to prevent surface adsorption. Reconstituted aqueous solutions stored at 2°C to 8°C should be utilized within 14 to 21 days. Repeated freeze-thaw cycles must be rigorously avoided, as phase transitions accelerate hydrolytic cleavage of the amide peptide bonds.
Ensuring experimental reproducibility requires sourcing peptides from manufacturing facilities operating under strict Quality Management Systems (QMS). Every lot of KPV synthesized for PX1 Research undergoes stringent processing within cGMP-compliant, ISO 17025-accredited USA facilities, guaranteeing absolute lot traceability from raw amino acid coupling through final sterile filtration.
We eliminate supply chain variability by attaching an independent, third-party laboratory Certificate of Analysis to every shipment. To support time-sensitive preclinical trial schedules, all orders confirmed Monday through Friday ship same-day from our strategically positioned distribution hubs in California and Arizona.
What does a standard kpv coa verify?
A standard KPV COA verifies the peptide's chromatographic purity (typically ≥98% by RP-HPLC), exact mass identity (via ESI-MS matching the 341.45 g/mol molecular weight), residual solvent levels, and bacterial endotoxin compliance (<0.01 EU/mg).
What is the standard concentration for a kpv 10mg/vial research sample?
A KPV 10mg/vial sample contains 10 milligrams of purified, lyophilized Lys-Pro-Val tripeptide powder. When reconstituted with 2.0 mL of diluent, it yields a working stock concentration of 5.0 mg/mL (approx. 14.64 mM).
How should a kpv 10mg vial be stored prior to reconstitution?
Prior to reconstitution, a sealed KPV 10mg vial should be stored desiccated at -20°C or -80°C, protected from ambient light. This preserves chemical integrity and prevents hydrolytic degradation for up to two years.
What analytical method confirms the sequence mass on a KPV COA?
Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) is utilized to measure the exact mass-to-charge ratio (m/z) of the [M+H]+ ion, matching theoretical KPV mass.
Why is endotoxin testing critical for KPV intestinal barrier assays?
Endotoxins (LPS) trigger inflammatory responses in cell culture and tissue models. Low endotoxin levels (<0.01 EU/mg) ensure that observed cellular changes stem solely from KPV signaling rather than bacterial contamination.
What cellular transporter mediates KPV uptake in preclinical models?
In vitro studies demonstrate that KPV is actively transported across epithelial cell membranes via the H+-coupled oligopeptide transporter PepT1 (SLC15A1).
How does KPV compare to BPC-157 in inflammatory bowel research?
KPV acts primarily as a direct intracellular modulator of NF-κB transcription via PepT1 entry, whereas BPC-157 drives tissue repair via growth factor modulation, nitric oxide pathway activation, and focal adhesion dynamics.
What diluent is recommended for reconstituting a KPV 10mg vial?
Sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile PBS (pH 7.4) is recommended for reconstituting KPV 10mg vials, depending on whether multi-use sampling or immediate cell culture placement is required.
How does lot traceability protect laboratory reproducibility?
Lot traceability links every distributed vial directly to its specific synthesis batch, RP-HPLC run, mass spectrum report, and raw material logs, allowing researchers to eliminate batch variations across long-term studies.
Can institutional buyers set up bulk procurement accounts for KPV?
Yes, academic and industrial research institutions can establish bulk ordering protocols and standardized lot-reservation schedules via the PX1 Research wholesale account portal.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.